Analyst Price Targets — HEPA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 1, 2022 12:00 am | Kristen Kluska | Cantor Fitzgerald | $70.00 | $24.60 | Pulse 2.0 | Hepion Pharmaceuticals (HEPA) Stock: Why It Jumped Up Today |
Latest News for HEPA
Risk and Volatility MusclePharm has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Valuation and Earnings This table compares MusclePharm and Hepion Pharmaceuticals"s revenue, earnings
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from Cirna…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HEPA.
U.S. House Trading
No House trades found for HEPA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.